Seed and Series A VC with $37M under management, investing in breakthrough longevity companies.
Longevity Fund companies have collected >$500M in follow-on funding, resulting in the 2018 IPO of the first company dedicated to reversing the diseases of aging, and multiple programs in clinic to reverse or prevent age-related disease.